Wang Junjun, Ling Liqun, Chen Shuhui, Chou Lunan, Wang Yumin, Hu Lijuan
Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Lab Med. 2024 May 2;55(3):271-276. doi: 10.1093/labmed/lmad076.
The aim of this study was to investigate the diagnostic potential of Krebs von den Lungen-6 (KL-6) in differentiating between malignant pleural effusion (MPE) induced by non-small cell lung cancer (NSCLC) and benign pleural effusion (BPE).
We collected 143 pleural effusion samples from August 2018 to March 2021. The samples included 91 cases of MPE and 52 cases of BPE. The KL-6 and other indicators in pleural effusion were detected.
The level of pleural effusion KL-6 (pKL-6) in the MPE group was significantly higher than in the BPE group (Mann-Whitney U = 442.500, P = .000). The area under the curve (AUC) of pKL-6/pleural effusion adenosine deaminase (pADA) + pleural effusion carcinoembryonic antigen (pCEA)/pADA (AUC = 0.992) in diagnosing MPE was higher than that of pKL-6 alone (AUC = 0.903), with a sensitivity of 93.26% and specificity of 100%.
The measurement of pKL-6 can differentiate NSCLC-induced MPE from BPE. Furthermore, the combined detection of pKL-6/pADA and pCEA/pADA can significantly improve the diagnostic efficiency for distinguishing NSCLC-induced MPE.
本研究旨在探讨克雷布斯-冯-登-卢肯斯-6（KL-6）在鉴别非小细胞肺癌（NSCLC）所致恶性胸腔积液（MPE）和良性胸腔积液（BPE）方面的诊断潜力。
我们收集了2018年8月至2021年3月期间的143份胸腔积液样本。样本包括91例MPE和52例BPE。检测了胸腔积液中的KL-6及其他指标。
MPE组胸腔积液KL-6（pKL-6）水平显著高于BPE组（曼-惠特尼U = 442.500，P = .000）。pKL-6/胸腔积液腺苷脱氨酶（pADA）+胸腔积液癌胚抗原（pCEA）/pADA诊断MPE的曲线下面积（AUC = 0.992）高于单独pKL-6（AUC = 0.903），敏感性为93.26%，特异性为100%。
检测pKL-6可鉴别NSCLC所致MPE与BPE。此外，联合检测pKL-6/pADA和pCEA/pADA可显著提高鉴别NSCLC所致MPE的诊断效率。
